Shanghai Bio-heart Biological Technology Co., Ltd.

Research Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK) on Bullrun: market cap HKD 287.23M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Ticker2185.HK
ExchangeHK
CountryChina
SectorHealthcare
IndustryBiotechnology
CurrencyHKD
Market capHKD 287.23M
Financial periodFY2025
RevenueCNY 44.93M
Net income-CNY 70.05M
Free cash flow-CNY 75.30M
Gross margin40.1%

Valuation Snapshot

latest market cap is HKD 287.23M.

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	CNY 44.93M	-CNY 70.05M	-CNY 75.30M	40.1%	n/a	CNY 92.28M	CNY 12.73M	CNY 434.82M
FY2024	CNY 0	-CNY 87.94M	-CNY 165.58M	n/a	-0.36	CNY 202.39M	CNY 8.28M	CNY 660.47M
FY2023	CNY 0	-CNY 175.89M	-CNY 67.00M	n/a	-0.72	CNY 369.44M	CNY 1.76M	CNY 748.41M
FY2022	CNY 0	-CNY 204.24M	-CNY 170.65M	n/a	-0.84	CNY 451.32M	CNY 18.11M	CNY 883.21M
FY2021	n/a	n/a	n/a	n/a	-1.64	n/a	n/a	n/a

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-18	HKD 287.23M	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 HKD.

About Shanghai Bio-heart Biological Technology Co., Ltd.

Shanghai Bio-heart Biological Technology Co., Ltd., together with its subsidiaries, engages in the research, development, and commercialization of invasive treatment products in China. The company develops Bioheart, a bioresorbable scaffolds system, which is in registration stage for percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis, a renal denervation system, which is in clinical stage for the treatment of uncontrolled hypertension and resistant hypertension;

Related stock research

China stocks China Healthcare stocks A-Z stock index

Other Healthcare stocks

Hualan Biological Engineering INC (002007.SZ) Shanghai RAAS Blood Products Co Ltd (002252.SZ) Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ) Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) CANbridge Pharmaceuticals Inc. (1228.HK) 3D Medicines Inc. (1244.HK) Ocumension Therapeutics (1477.HK) 3SBio Inc. (1530.HK) LongBio Pharma (Suzhou) Co., Ltd. (1779.HK) Innovent Biologics, Inc. (1801.HK) Viva Biotech Holdings (1873.HK) BioDlink International Company Limited (1875.HK)

Frequently asked questions

What is Shanghai Bio-heart Biological Technology Co., Ltd.'s market cap?

Shanghai Bio-heart Biological Technology Co., Ltd.'s market capitalization is HKD 287.23M.

What does Shanghai Bio-heart Biological Technology Co., Ltd. do?

Shanghai Bio-heart Biological Technology Co., Ltd., together with its subsidiaries, engages in the research, development, and commercialization of invasive treatment products in China.